Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic macular edema (DME). The DME therapy market became more competitive with the launch of vascular endothelial growth factor (VEGF) inhibitors—approved agents Eylea and Lucentis—which are the standards of care for center-involved DME. Ozurdex and Iluvien, both long-acting corticosteroid implants, are also approved for DME in some markets. Of note, Lucentis 0.3 mg (0.5 mg in Europe) and Eylea are now both approved for DR without DME. Factoring in the near-term launch of biosimilars of Lucentis 0.5 mg and Eylea, growing clinical data supporting the treatment of some DR patients without DME with pharmacotherapies, and a dynamic development pipeline, competition is expected to increase in this space.
- How large is the treatable DR / DME population, and how will diagnosis / drug-treatment rates change over time?
- Do KOLs perceive any differences between Avastin, Eylea, and Lucentis? How is the use of these drugs expected to change over the next ten years as emerging therapies enter the market? How are Iluvien and Ozurdex being used to treat DME?
- How will market dynamics be impacted by the launch of biosimilars of Lucentis 0.5 mg and Eylea?
- How have Lucentis and Eylea been incorporated into the treatment algorithm for DR exclusive of DME in the United States? What would be the impact of Novartis’s brolucizumab if it is successfully launched for DME and PDR?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading retinal specialists and supported by survey data collected for this and other DRG research.
Epidemiology: Prevalence of severe NPDR, PDR, and DME, by country, including diagnosed / drug-treated populations.
Forecast: Ten-year, annualized, drug-level sales and patient share of key DR and DME therapies through 2029, segmented by brands / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III / PR: 5 drugs; Phase II: 12 drugs.